These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3295020)

  • 1. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.
    Morgan MY; Hawley KE; Stambuk D
    J Hepatol; 1987 Apr; 4(2):236-44. PubMed ID: 3295020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
    Morgan MY; Hawley KE
    Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
    Morgan MY; Alonso M; Stanger LC
    J Hepatol; 1989 Mar; 8(2):208-17. PubMed ID: 2654285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose.
    Riggio O; Balducci G; Ariosto F; Merli M; Tremiterra S; Ziparo V; Capocaccia L
    Hepatogastroenterology; 1990 Oct; 37(5):524-7. PubMed ID: 2253931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.
    Lanthier PL; Morgan MY
    Gut; 1985 Apr; 26(4):415-20. PubMed ID: 3979914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
    Heredia D; Terés J; Orteu N; Rodés J
    J Hepatol; 1988 Aug; 7(1):106-10. PubMed ID: 3053887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.
    Riggio O; Balducci G; Ariosto F; Merli M; Pieche U; Pinto G; Tremiterra S; Ziparo V; Capocaccia L
    Dig Dis Sci; 1989 Jun; 34(6):823-9. PubMed ID: 2656134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.
    Heredia D; Caballería J; Arroyo V; Ravelli G; Rodés J
    J Hepatol; 1987 Jun; 4(3):293-8. PubMed ID: 3598162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients].
    Grandi M; Sacchetti C; Pederzoli S; Celani MF
    Minerva Gastroenterol Dietol; 1991; 37(4):225-30. PubMed ID: 1805974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy.
    Patil DH; Westaby D; Mahida YR; Palmer KR; Rees R; Clark ML; Dawson AM; Silk DB
    Gut; 1987 Mar; 28(3):255-9. PubMed ID: 3570029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis.
    Blanc P; Daures JP; Rouillon JM; Peray P; Pierrugues R; Larrey D; Gremy F; Michel H
    Hepatology; 1992 Feb; 15(2):222-8. PubMed ID: 1531204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis.
    Cammà C; Fiorello F; Tinè F; Marchesini G; Fabbri A; Pagliaro L
    Dig Dis Sci; 1993 May; 38(5):916-22. PubMed ID: 8482191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study.
    Pai CH; Huang YS; Jeng WC; Chan CY; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jan; 55(1):31-6. PubMed ID: 7712392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonabsorbable disaccharides for hepatic encephalopathy.
    Als-Nielsen B; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2004; (2):CD003044. PubMed ID: 15106187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [1st use of lactitol in the treatment of porto-systemic encephalopathy].
    Bircher J; Bührer M; Franz K; van Velthuijsen JA
    Schweiz Med Wochenschr; 1982 Sep; 112(38):1306-7. PubMed ID: 7134954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of lactulose and lactitol administration on fecal fat excretion in patients with liver cirrhosis.
    Merli M; Caschera M; Piat C; Pinto G; Diofebi M; Riggio O
    J Clin Gastroenterol; 1992 Sep; 15(2):125-7. PubMed ID: 1401823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
    Morgan MY
    Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.